The phase 3 GLISTEN trial has been evaluating the candidate in adults with PBC and cholestatic pruritus, or relentless itch, ...

July 07, 2004 Carolias Disease? Diagnostic choices in this case include melanoma and hepatoma.... CTisus, May 01, 2004 A 14-Year-Old Boy With Jaundice and Pruritus This patient presented to his ...

The therapy aims to treat adults with cholestatic pruritus (itch) and primary biliary cholangitis (PBC), an autoimmune liver condition. The trial met its primary endpoint, which was the change from ...

The VANTAGE study is evaluating volixibat in patients with cholestatic pruritus caused by primary biliary cholangitis (PBC). “The extended VANTAGE analysis provides encouraging insights into the ...

Seventy percent of patients treated with volixibat experienced a ≥50% reduction in serum bile acids - Volixibat treated patients experienced reductions in IL-31 FOSTER CITY, Calif., May 09, ...

Interim results from the ongoing Phase III ASSURE trial demonstrated that Livdelzi maintained a consistent biochemical response in patients with primary biliary cholangitis ... improvements in ...

Top-line results from the Phase III GLISTEN trial (NCT04950127) show that the novel therapy linerixibat produced a significant reduction in pruritus in adult patients with primary biliary cholangitis ...

Linerixibat, an investigational oral ileal bile acid transporter (IBAT) inhibitor, improved cholestatic pruritus in patients with primary biliary cholangitis (PBC), the randomized phase III GLISTEN ...

Investigators enrolled 238 people with the liver disease primary biliary cholangitis and cholestatic pruritus, a medical term for relentless itch. After 24 weeks of oral dosing, scores on a 10 ...